Statins for age-related macular degeneration

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 8, 2016, Pages

  Gehlbach, Peter ^a   Li, Tianjing ^b   Hatef, Elham ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ADVERSE OUTCOME; AGE RELATED MACULAR DEGENERATION; ARTICLE; CHOLESTEROL BLOOD LEVEL; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; LOW DRUG DOSE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SYSTEMATIC REVIEW; VISION; VISUAL ACUITY; FEMALE; MACULAR DEGENERATION; MALE; MIDDLE AGED;

FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MACULAR DEGENERATION; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIMVASTATIN; VISUAL ACUITY;

EID: 84982698553     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006927.pub5     Document Type: Article

References (55)

1. Guymer RH, Baird PN, Varsamidis M, Busija L, Dimitrov PN, Aung KZ, et al. Proof of concept, randomized, placebo-controlled study of the effect of simvastatin on the course of age-related macular degeneration. PLoS One 2013;8(12):e83759.
2. Guymer RH, Chiu A, Robman L, O'Loughlin RK, Tikellis G, Dimitrov P, et al. Slowing progression of age-related macular degeneration with statins: a randomised, controlled clinical trial. Investigative Ophthalmology and Visual Science 2003;44:ARVO E-abstract 1807.
3. Guymer RH, Dimitrov PN, Varsamidis M, Lim LL, Baird PN, Vingrys AJ, et al. Can HMG Co-A reductase inhibitors ("statins") slow the progression of age-related macular degeneration? The age-related maculopathy statin study (ARMSS). Clinical Interventions in Aging 2008;3(3):581-93.
4. Guymer RH, Robman L, Varsamidis M, Dimitrov P, Hunt N, Lim L, et al. Can HMG Co-A reductase inhibitors ("statins") slow the progression of AMD?. Investigative Ophthalmology and Visual Sciences 2005; Vol. 46:ARVO E-abstract 2364.
5. Martini E, Scorolli L, Burgagni MS, Fessehaie S. Evaluation of the retinal effects of simvastatin in patients with age-related macular degeneration [Valutazione degli effetti retinici della somministrazione di simvastatina in pazienti affetti da degenerazione maculare senile]. Annali Di Ottalmologia e Clinica Oculistica 1991;117(11):1121-6.
6. Berendschot TT, Plat J, de Jong A, Mensink RP. Long-term plant stanol and sterol ester-enriched functional food consumption, serum lutein/zeaxanthin concentration and macular pigment optical density. British Journal of Nutrition 2009;101(11):1607-10.
7. Della Valle V, Scorolli L, Meduri R. Retinal effects of Simvastatin in SMD: Cases up-date [Effetti retinici della Simvastatina nella DMS: Aggiornamento casistica]. Annali Di Ottalmologia e Clinica Oculistica 2000;126(11-12):249-55.
8. Della Valle V, Scorolli L, Meduri R. Retinal effects of Simvastatin in patients affected by age related macular degeneration [Effetti retinici della Simvastatina in pazienti affetfi da degenerazione maculare senile correlata all'eta]. Annali Di Ottalmologia e Clinica Oculistica 2000;126(5-6):89-95.
9. Drobek-Slowik M, Karczewicz D, Safranow K, Jakubowska K, Chlubek D. Use of statins as a form of protection against age-related macular degeneration (AMD) [Leczenie statynami jako forma ochrony przed zwyrodnieniem plamki zwiazanym z wiekiem (AMD)]. Klinika Oczna 2008;1-3:50-4.
10. Maguire MG, Ying GS, McCannel CA, Liu C, Dai Y, Complications of Age-related Macular Degeneration Prevention Trial (CAPT) Research Group. Statin use and the incidence of advanced age-related macular degeneration in the Complications of Age-related Macular Degeneration Prevention Trial. Ophthalmology 2009;116(12):2381-5.
11. Mao YQ, Qi XY, Peng W, Sun JX, Wang AP. Effect of lovastatin on hemodynamic changes in early stage patients with age-related macular degeneration. International Journal of Ophthalmology 2009;9(8):1521-3.
12. Sen K, Misra A, Kumar A, Pandey RM. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Research and Clinical Practice 2002;56(1):1-11.
13. American Academy of Ophthalmology. Preferred Practice Pattern Guidelines. Age-Related Macular Degeneration. www.aao.org/ppp (accessed 7 November 2014).
14. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology 2001;119(10):1417-36.
15. Complications of Age-Related Macular Degeneration Prevention Trial Study Group. The Complications of Age-Related Macular Degeneration Prevention Trial (CAPT): rationale, design and methodology. Clinical Trials 2004;1(1):91-107.
16. Congdon NG, Friedman DS, Lietman T. Important causes of visual impairment in the world today. JAMA 2003;290(15):2057-60.
17. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
18. Dichtl W, Dulak J, Frick M, Alber HF, Schwarzacher SP, Ares MPS, et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arteriosclerosis, Thrombosis, and Vascular Biology 2003;23(1):58-63.
19. Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. Cochrane Database of Systematic Reviews 2012, Issue 6. [DOI: 10.1002/14651858.CD000253.pub3]
20. Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database of Systematic Reviews 2012, Issue 11. [DOI: 10.1002/14651858.CD000254.pub3]
21. Friedman E. Update of the vascular model of AMD. British Journal of Ophthalmology 2004;88(2):161-3.
22. Geltzer A, Turalba A, Vedula SS. Surgical implantation of steroids with antiangiogenic characteristics for treating neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2013, Issue 1. [DOI: 10.1002/14651858.CD005022.pub3]
23. Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130-6.
24. Gurne DH, Tso MO, Edward DP, Ripp H. Antiretinal antibodies in serum of patients with age-related macular degeneration. Ophthalmology 1991;98(5):602-7.
25. Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. Journal of Clinical Epidemiology 2011;64(4):380-2.
26. Guymer RH, Chiu AW, Lim L, Baird PN. HMG CoA reductase inhibitors (statins): do they have a role in age-related macular degeneration?. Survey of Ophthalmology 2005;50(2):194-206.
27. Hall NF, Gale CR, Syddall H, Phillips DI, Martyn CN. Risk of macular degeneration in users of statins: cross sectional study. BMJ 2001;323(7309):375-6.
28. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
29. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992;99(6):933-43.
30. Klein R, Klein BE, Jensen SC, Cruickshanks KJ, Lee KE, Danforth LG, et al. Medication use and the 5-year incidence of early age-related maculopathy: The Beaver Dam Eye Study. Archives of Ophthalmology 2001;119(9):1354-9.
31. Klein R, Klein BE, Tomany SC, Meuer SM, Huang GH. Ten-year incidence and progression of age-related maculopathy: The Beaver Dam Eye Study. Ophthalmology 2002;109(10):1767-79.
32. Klein R, Deng Y, Klein BE, Hyman L, Seddon J, Frank RN, et al. Cardiovascular disease, its risk factors and treatment, and age-related macular degeneration: Women's Health Initiative Sight Exam ancillary study. Ophthalmology 2007;143(3):473-83.
33. Klein R, Knudtson MD, Klein BE. Statin use and the five-year incidence and progression of age-related macular degeneration. American Journal of Ophthalmology 2007;144(1):1-6.
34. Li T, Hutfless S, Scharfstein DO, Daniels MJ, Hogan JW, Little RJ, et al. Standards should be applied in the prevention and handling of missing data for patient-centered outcomes research: a systematic review and expert consensus. Journal of Clinical Epidemiology 2013;67(1):15-32.
35. McGwin G Jr, Owsley C, Curcio CA, Crain RJ. The association between statin use and age related maculopathy. British Journal of Ophthalmology 2003;87(9):1121-5.
36. McGwin G, Modjarrad K, Hall TA, Xie A, Owsley C. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the presence of age-related macular degeneration in the Cardiovascular Health Study. Archives of Ophthalmology 2006;124(1):33-7.
37. Mitchell P, Smith W, Attebo K, Wang JJ. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology 1995;102(10):1450-60.
38. Anonymous Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. Archives of Ophthalmology 1991;109(8):1109-14.
39. Anonymous Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. Archives of Ophthalmology 1994;112(4):500-9.
40. Penfold PL, Madigan MC, Gillies MC, Provis JM. Immunological and aetiological aspects of macular degeneration. Progress in Retinal and Eye Research 2001;20(3):385-414.
41. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
42. Sagara N, Kawaji T, Takano A, Inomata Y, Inatani M, Fukushima M, et al. Effect of pitavastatin on experimental choroidal neovascularization in rats. Experimental Eye Research 2007;84(6):1074-80.
43. Smeeth L, Cook C, Chakravarthy U, Hubbard R, Fletcher AE. A case control study of age related macular degeneration and use of statins. British Journal of Ophthalmology 2005;89(9):1171-5.
44. Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. British Journal of Clinical Pharmacology 2009;67(1):99-109.
45. Smith W, Assink J, Klein R, Mitchell P, Klaver CC, Klein BE, et al. Risk factors for age-related macular degeneration: Pooled findings from three continents. Ophthalmology 2001;108(4):697-704.
46. Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2014, Issue 8. [DOI: 10.1002/14651858.CD005139.pub3]
47. Spaide RF, Ho-Spaide WC, Browne RW, Armstrong D. Characterization of peroxidized lipids in Bruch's membrane. Retina 1999;19(2):141-7.
48. Tan JS, Mitchell P, Rochtchina E, Wang JJ. Statins and the long-term risk of incident age-related macular degeneration: The Blue Mountains Eye Study. American Journal of Ophthalmology 2007;143(4):685-7.
49. van Leeuwen R, Vingerling JR, Hofman A, de Jong PT, Stricker BH. Cholesterol lowering drugs and risk of age related maculopathy: prospective cohort study with cumulative exposure measurement. BMJ 2003;326(7383):255-6.
50. Virgili G, Bini A. Laser photocoagulation for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD004763.pub2]
51. Wormald R, Evans J, Smeeth L, Henshaw K. Photodynamic therapy for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD002030.pub3]
52. Gehlbach P, Li T, Hatef E. Statins for age-related macular degeneration. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD006927]
53. Gehlbach P, Li T, Hatef E. Statins for age-related macular degeneration. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD006927.pub2]
54. Gehlbach P, Li T, Hatef E. Statins for age-related macular degeneration. Cochrane Database of Systematic Reviews 2012, Issue 3. [DOI: 10.1002/14651858.CD006927.pub3]
55. Gehlbach P, Li T, Hatef E. Statins for age-related macular degeneration. Cochrane Database of Systematic Reviews 2015, Issue 2. [DOI: 10.1002/14651858.CD006927.pub4]